CEO Dipal Doshi was paid $3,837,737 in fiscal year 2025, ↓ down 1.4% from fiscal year 2024 (SEC filing 0001689375-26-000021 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,837,737 ↓ Dipal Doshi total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
TRDA's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dipal Doshi | $635,000 | $0 | $1,387,428 | $1,452,059 | $349,250 | $0 | $14,000 | $3,837,737 |
| Chief Executive Officer | ||||||||
| Natarajan Sethuraman | 520,000 | 0 | 725,952 | 760,363 | 234,000 | 0 | 14,000 | 2,254,315 |
| President of Research and Development | ||||||||
| Nathan Dowden | 499,200 | 0 | 725,952 | 760,363 | 224,640 | 0 | 13,342 | 2,223,497 |
| President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dipal Doshi | $3,837,737 | $3,891,503 | — | ↓ −53,766 |
| Natarajan Sethuraman | 2,254,315 | 1,962,700 | — | ↑ +291,615 |
| Nathan Dowden | 2,223,497 | 2,460,688 | — | ↓ −237,191 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Entrada Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TRDA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name TRDA as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Dipal Doshi | CEO | $3,837,737 |
| Natarajan Sethuraman | President | $2,254,315 |
| Nathan Dowden | President | $2,223,497 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Bernhardt Zeiher, M.D | Independent Director | $150,680 |
| Gina Chapman | Independent Director | $157,553 |
| Kush M. Parmar, M.D., Ph.D | Chair of the Board | $202,597 |
| Maha Radhakrishnan, M.D | Independent Director | $230,927 |
| Mary Thistle | Independent Director | $167,427 |
| Peter S. Kim, Ph.D | Director | $144,388 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nathan Dowden | President & COO | 2026-05-04 | D | 15,000 | $15 | $229,953 | Common | Form 4 ↗ |
| Natarajan Sethuraman | President, Research & Develop. | 2026-05-04 | D | 25,907 | 15 | 398,810 | Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-05-04 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-05-04 | A | 15,000 | 2 | 26,100 | Common | Form 4 ↗ |
| Bernhardt G. Zeiher | Director | 2026-05-20 | A | 5,000 | 6 | 29,316 | Common, indirect | Form 4 ↗ |
| Bernhardt G. Zeiher | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Thistle | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Maha Radhakrishnan | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gina Chapman | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter S. Kim | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kush Parmar | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kush Parmar | Director | 2026-07-30 | D | 114,756 | 7 | 795,259 | Common, indirect | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-07-30 | D | 114,756 | 7 | 795,259 | Common, indirect | Form 4 ↗ |
| Kush Parmar | Director | 2026-07-31 | D | 1,718 | 7 | 11,768 | Common | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-07-31 | D | 1,718 | 7 | 11,768 | Common, indirect | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-08-06 | D | 10,494 | 7 | 73,458 | Common, indirect | Form 4 ↗ |
| Kush Parmar | Director | 2026-08-06 | D | 10,494 | 7 | 73,458 | Common, indirect | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-08-07 | D | 52,317 | 7 | 358,371 | Common, indirect | Form 4 ↗ |
| Kush Parmar | Director | 2026-08-07 | D | 52,317 | 7 | 358,371 | Common | Form 4 ↗ |
| Kush Parmar | Director | 2026-08-10 | D | 92,444 | 7 | 647,108 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-24 | D | 21,623 | 7 | 158,713 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-24 | D | 21,623 | 7 | 158,713 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-25 | D | 26,522 | 8 | 199,976 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-25 | D | 26,522 | 8 | 199,976 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-26 | D | 14,569 | 7 | 102,857 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-26 | D | 14,569 | 7 | 102,857 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-27 | D | 38,922 | 7 | 280,238 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-27 | D | 38,922 | 7 | 280,238 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-28 | D | 3,733 | 7 | 26,168 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-28 | D | 3,733 | 7 | 26,168 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-31 | D | 44,259 | 7 | 309,370 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-31 | D | 44,259 | 7 | 309,370 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-01 | D | 29,088 | 7 | 205,361 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-01 | D | 29,088 | 7 | 205,361 | Common, indirect | Form 4 ↗ |
| Dipal Doshi | Director | 2026-09-02 | D | 8,724 | 7 | 62,323 | Common | Form 4 ↗ |
| Natarajan Sethuraman | President, Research & Develop. | 2026-09-02 | D | 2,079 | 7 | 14,852 | Common | Form 4 ↗ |
| Kory James Wentworth | Chief Financial Officer | 2026-09-02 | D | 1,733 | 7 | 12,380 | Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-09-02 | D | 2,528 | 7 | 18,060 | Common | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-02 | D | 25,131 | 7 | 180,692 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-02 | D | 25,131 | 7 | 180,692 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-03 | D | 32,263 | 7 | 231,326 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-03 | D | 32,263 | 7 | 231,326 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-04 | D | 38,500 | 7 | 273,735 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-04 | D | 38,500 | 7 | 273,735 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-08 | D | 192,500 | 7 | 1,426,425 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-08 | D | 192,500 | 7 | 1,426,425 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-09 | D | 28,837 | 7 | 205,608 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-09 | D | 28,837 | 7 | 205,608 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Nathan Dowden | Option | — | — | — | — | — | $760,363 |
| Dipal Doshi | PSU | — | — | — | — | — | 1,387,428 |
| Natarajan Sethuraman | Option | — | — | — | — | — | 760,363 |
| Dipal Doshi | Option | — | — | — | — | — | 1,452,059 |
| Nathan Dowden | PSU | — | — | — | — | — | 725,952 |
| Natarajan Sethuraman | PSU | — | — | — | — | — | 725,952 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Nathan Dowden | $0 | $725,952 | $760,363 | 48.8% |
| Dipal Doshi | 0 | 1,387,428 | 1,452,059 | 48.9% |
| Natarajan Sethuraman | 0 | 725,952 | 760,363 | 48.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Natarajan Sethuraman | Option | 9,406 | 15.41 | — |
| Dipal Doshi | Option | 11,344 | 11.57 | — |
| Nathan Dowden | RSU | 24,825 | — | 255,201 |
| Natarajan Sethuraman | RSU | 7,100 | — | 72,988 |
| Nathan Dowden | RSU | 7,100 | — | 72,988 |
| Natarajan Sethuraman | Option | 4,345 | 11.57 | — |
| Natarajan Sethuraman | RSU | 80,000 | — | 822,400 |
| Nathan Dowden | RSU | 2,816 | — | 28,948 |
| Nathan Dowden | Option | 9,406 | 15.41 | — |
| Nathan Dowden | Option | 28,181 | 13.73 | — |
| Dipal Doshi | RSU | 116,200 | — | 1,194,536 |
| Dipal Doshi | RSU | 100,000 | — | 1,028,000 |
| Nathan Dowden | RSU | 30,000 | — | 308,400 |
| Dipal Doshi | RSU | 24,825 | — | 255,201 |
| Dipal Doshi | RSU | 3,781 | — | 38,869 |
| Nathan Dowden | RSU | 1,408 | — | 14,474 |
| Dipal Doshi | Option | 32,922 | 15.41 | — |
| Natarajan Sethuraman | Option | 5,070 | 12 | — |
| Dipal Doshi | RSU | 78,525 | — | 807,237 |
| Natarajan Sethuraman | RSU | 33,075 | — | 340,011 |
| Dipal Doshi | RSU | 7,562 | — | 77,737 |
| Natarajan Sethuraman | RSU | 1,448 | — | 14,885 |
| Dipal Doshi | Option | 13,234 | 12 | — |
| Nathan Dowden | Option | 6,719 | 12.25 | — |
| Natarajan Sethuraman | RSU | 2,897 | — | 29,781 |
| Natarajan Sethuraman | Option | 90,800 | 11.94 | — |
| Natarajan Sethuraman | Option | 37,575 | 13.73 | — |
| Nathan Dowden | Option | 4,223 | 11.57 | — |
| Nathan Dowden | Option | 4,927 | 12 | — |
| Nathan Dowden | Option | 90,800 | 11.94 | — |
| Dipal Doshi | Option | 23,516 | 12.25 | — |
| Dipal Doshi | Option | 89,156 | 13.73 | — |
| Dipal Doshi | Option | 173,400 | 11.94 | — |
| Nathan Dowden | RSU | 60,000 | — | 616,800 |
| Nathan Dowden | RSU | 60,800 | — | 625,024 |
| Natarajan Sethuraman | Option | 6,719 | 12.25 | — |
| Natarajan Sethuraman | RSU | 60,800 | — | 625,024 |
Compensation for named executive officers consists of a combination of base salary, cash bonuses, and long-term incentive compensation in the form of stock options, RSUs and PSUs, designed to be competitive and aligned with the company's business and executive talent requirements.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Maha Radhakrishnan, M.DIndependent · Audit · Newly elected | $28,538 | $0 | $202,388 | — | $0 | $230,927 |
| Kush M. Parmar, M.D., Ph.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance (Chair) | 98,209 | 0 | 104,388 | — | 0 | 202,597 |
| Mary ThistleIndependent · Audit (Chair) · Compensation | 63,038 | 0 | 104,388 | — | 0 | 167,427 |
| Gina ChapmanIndependent · Audit · Nominating/Governance | 53,165 | 0 | 104,388 | — | — | 157,553 |
| Bernhardt Zeiher, M.DIndependent · Compensation | 46,291 | 0 | 104,388 | — | 0 | 150,680 |
| Peter S. Kim, Ph.DNot independent | 40,000 | 0 | 104,388 | — | 0 | 144,388 |
| Dipal DoshiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 9,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $329,241 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $329,241 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Entrada Therapeutics | 2025 | Dipal Doshi | $635,000 | $1,387,428 | $1,452,059 | $349,250 | $3,837,737 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Dipal Doshi | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “2025 Summary Compensation Table”. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900 |
| 2 | Section 01, Natarajan Sethuraman | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “2025 Summary Compensation Table”. As printed: 2,254,315. Filing ↗machine: t12 · r4 · c14 · span 341380–341389 |
| 3 | Section 01, Nathan Dowden | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “2025 Summary Compensation Table”. As printed: 2,223,497. Filing ↗machine: t12 · r6 · c14 · span 345914–345923 |
| 4 | Section 03, Nathan Dowden Option | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r6 · c8 · span 344988–344995 |
| 5 | Section 03, Dipal Doshi PSU | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c6 · span 335548–335557 |
| 6 | Section 03, Natarajan Sethuraman Option | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r4 · c8 · span 340604–340611 |
| 7 | Section 03, Dipal Doshi Option | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c8 · span 335885–335894 |
| 8 | Section 03, Nathan Dowden PSU | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r6 · c6 · span 344679–344686 |
| 9 | Section 03, Natarajan Sethuraman PSU | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r4 · c6 · span 340345–340352 |
| 10 | Section 07, pay ratio | 10-K | 2026-02-26 | 0001689375-26-000011 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, Maha Radhakrishnan, M.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 230,927. Filing ↗machine: span 529796–530012 |
| 12 | Section 08, Kush M. Parmar, M.D., Ph.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 202,597. Filing ↗machine: span 525189–525430 |
| 13 | Section 08, Mary Thistle | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 167,427. Filing ↗machine: t16 · r3 · c7 · span 523556–523772 |
| 14 | Section 08, Gina Chapman | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 157,553. Filing ↗machine: t16 · r6 · c7 · span 528305–528546 |
| 15 | Section 08, Bernhardt Zeiher, M.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 150,680. Filing ↗machine: span 526674–526890 |
| 16 | Section 08, Peter S. Kim, Ph.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 144,388. Filing ↗machine: span 522044–522316 |
| 17 | Section 08, Dipal Doshi | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 02, Nathan Dowden 2026-05-04 | Form 4 | 2026-05-04 | 0001873392-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Natarajan Sethuraman 2026-05-04 | Form 4 | 2026-05-04 | 0001873394-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Nathan Dowden 2026-05-04 | Form 4 | 2026-05-04 | 0001873392-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Nathan Dowden 2026-05-04 | Form 4 | 2026-05-04 | 0001873392-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Bernhardt G. Zeiher 2026-05-20 | Form 4 | 2026-05-21 | 0001689375-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Bernhardt G. Zeiher 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Mary Thistle 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Maha Radhakrishnan 2026-06-10 | Form 4 | 2026-06-12 | 0002013423-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Gina Chapman 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Peter S. Kim 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Kush Parmar 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Kush Parmar 2026-07-30 | Form 4 | 2026-08-03 | 0001664281-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, 5AM Ventures V, L.P. 2026-07-30 | Form 4 | 2026-08-03 | 0001231919-26-000822 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Kush Parmar 2026-07-31 | Form 4 | 2026-08-03 | 0001664281-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, 5AM Ventures V, L.P. 2026-07-31 | Form 4 | 2026-08-03 | 0001231919-26-000822 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, 5AM Ventures V, L.P. 2026-08-06 | Form 4 | 2026-08-10 | 0001231919-26-000854 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Kush Parmar 2026-08-06 | Form 4 | 2026-08-10 | 0001664281-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, 5AM Ventures V, L.P. 2026-08-07 | Form 4 | 2026-08-10 | 0001231919-26-000854 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Kush Parmar 2026-08-07 | Form 4 | 2026-08-10 | 0001664281-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Kush Parmar 2026-08-10 | Form 4 | 2026-08-10 | 0001664281-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-24 | Form 4 | 2026-08-26 | 0001231919-26-001106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, MPM BioVentures 2014, L.P. 2026-08-24 | Form 4 | 2026-08-26 | 0001231919-26-001107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, MPM BioVentures 2014, L.P. 2026-08-25 | Form 4 | 2026-08-26 | 0001231919-26-001107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-25 | Form 4 | 2026-08-26 | 0001231919-26-001106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, MPM BioVentures 2014, L.P. 2026-08-26 | Form 4 | 2026-08-26 | 0001231919-26-001107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-26 | Form 4 | 2026-08-26 | 0001231919-26-001106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, MPM BioVentures 2014, L.P. 2026-08-27 | Form 4 | 2026-08-31 | 0001231919-26-001135 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-27 | Form 4 | 2026-08-31 | 0001231919-26-001136 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-28 | Form 4 | 2026-08-31 | 0001231919-26-001136 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, MPM BioVentures 2014, L.P. 2026-08-28 | Form 4 | 2026-08-31 | 0001231919-26-001135 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, MPM BioVentures 2014, L.P. 2026-08-31 | Form 4 | 2026-08-31 | 0001231919-26-001135 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-31 | Form 4 | 2026-08-31 | 0001231919-26-001136 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, MPM BioVentures 2014, L.P. 2026-09-01 | Form 4 | 2026-09-03 | 0001231919-26-001143 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-01 | Form 4 | 2026-09-03 | 0001231919-26-001144 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Dipal Doshi 2026-09-02 | Form 4 | 2026-09-03 | 0001613084-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Natarajan Sethuraman 2026-09-02 | Form 4 | 2026-09-03 | 0001873394-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Kory James Wentworth 2026-09-02 | Form 4 | 2026-09-03 | 0001725663-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Nathan Dowden 2026-09-02 | Form 4 | 2026-09-03 | 0001873392-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, MPM BioVentures 2014, L.P. 2026-09-02 | Form 4 | 2026-09-03 | 0001231919-26-001143 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-02 | Form 4 | 2026-09-03 | 0001231919-26-001144 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-03 | Form 4 | 2026-09-03 | 0001231919-26-001144 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, MPM BioVentures 2014, L.P. 2026-09-03 | Form 4 | 2026-09-03 | 0001231919-26-001143 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, MPM BioVentures 2014, L.P. 2026-09-04 | Form 4 | 2026-09-09 | 0001231919-26-001155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-04 | Form 4 | 2026-09-09 | 0001231919-26-001156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-08 | Form 4 | 2026-09-09 | 0001231919-26-001156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, MPM BioVentures 2014, L.P. 2026-09-08 | Form 4 | 2026-09-09 | 0001231919-26-001155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, MPM BioVentures 2014, L.P. 2026-09-09 | Form 4 | 2026-09-09 | 0001231919-26-001155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-09 | Form 4 | 2026-09-09 | 0001231919-26-001156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 67 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 68 | Section 09b board cost (computed) | Computed | — | — | Cash 329,241 + equity 0 + all other 0 = 329,241, summed across the director compensation table rows.machine: formula: Σ = 329,241 |
| 69 | Entrada Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001689375-26-000021 | CEO total compensation as printed in Entrada Therapeutics's own proxy. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.